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Letter 1
Incidence and Clinical Course of COVID-19 in Patients with 
Connective Tissue Diseases: A Descriptive Observational 
Analysis
To the Editor: 
The outbreak of COVID-19 in December 2019 in China has very quickly 
become a global health emergency, with almost 2 million infected patients 
worldwide1. Along with the spread of the pandemic, there has been growing 
concern about the management of fragile patients with rheumatic condi-
tions. There are still very few data available on this aspect. In particular, 
subjects affected by connective tissue diseases (CTD) are known to have 
an increased infectious risk compared to the healthy population because of 
a general impairment of the immune system intrinsic to the autoimmune 
disease itself, the iatrogenic effect linked to the use of immunosuppressive 
drugs, and the high number of comorbidities that often complicate the clin-
ical picture2,3. On the other hand, the progressive increase in the knowledge 
about the pathogenesis of the infection is paving the way for the use of 
certain drugs common in rheumatology to also treat COVID-194.
 As rheumatologists operating in one of the major epicenters of the 
pandemic (Milan, Italy), we conducted a survey to investigate the effect 
of COVID-19 on patients with CTD followed at the Research Center for 
Adult and Pediatric Rheumatic Diseases of the ASST Gaetano Pini-CTO. 
The survey included demographics, clinical information on the rheumatic 
disease, the incidence of COVID-19 confirmed by nasopharyngeal swab, 
the frequency of respiratory symptoms of suspected viral infections, and 
how the outbreak affected the patient’s behavior and the course of CTD. In 
the period between February 25 and March 25, 2020, the survey was admin-
istered face-to-face to patients who were assessed in the outpatient CTD 
clinic of our center or by telephone to those who missed an appointment 
scheduled for the same period.
 The overall study population included 123 adult patients (110 females) 
with systemic lupus erythematosus (n = 61), systemic sclerosis (SSc; 
n = 43), undifferentiated CTD (n = 9), or Sjögren syndrome (n = 10). The 
mean age (± SD) was 49.3 (14.4) years and the mean disease duration 10.2 
(8.7) years. About 60% of patients were treated with conventional synthetic 
disease-modifying drugs [31 hydroxychloroquine (HCQ), 22 mycophe-
nolate, 11 methotrexate, 8 azathioprine, and 1 cyclosporine], 25 patients 
were receiving biological agents [18 belimumab, 5 rituximab (RTX), and 
2 tocilizumab (TCZ)], and 64.2% were also taking corticosteroids (mean 
dose 5.3 mg daily). The only recorded patient with a COVID-19 positive 
swab was a 32-year-old woman with SSc and pulmonary involvement 
treated with HCQ and RTX. She developed a severe pattern of COVID-19 
interstitial pneumonia requiring hospitalization in intensive care, where, 
despite intubation and treatment with TCZ, the patient died. In the same 
period of observation, the incidence of COVID-19 positivity in our region 
(Lombardy) was consistent with what we observed in our cohort (0.62 vs 
0.81%, respectively)5. A further 14 patients reported respiratory symptoms 
consistent with a viral infection, but they did not have access to the swab. 
In these patients we observed a mild clinical course of infectious disease 
with a rapid resolution of symptoms. They did not require the discontin-
uation of ongoing rheumatological therapy and did not experience a CTD 
relapse. Among the latter group, 44.4% were taking HCQ therapy versus 
24.2% of patients who did not develop respiratory symptoms. These data 
were not consistent with the proposed protective effect of the drug against 
COVID-19 infection6. However, it is important to point out that to date, 
preliminary data have demonstrated the efficacy of antimalarials in the 
treatment of COVID-197, while at the moment no evidence is yet available 
about their potential prophylactic effect in the prevention of contagion8.
 Overall, of 123 patients, only 5 have discontinued their current rheu-
matological therapy (2 for fear of contagion and 3 upon indication of a 
non-rheumatologist consultant) and 115 have maintained stable disease 
activity without experiencing flares. 
 The vast majority of the study population (84.1%) reported to 
have adopted specific precautions to prevent the contagion such as 
social distancing (55.2%), use of masks (58.1%), and non-working or 
home-working (60.1% of workers) since the outbreak began. This positive 
propensity is likely to depend on the very fact of being carriers of a disease 
with increased infection risk and should certainly be taken into account 
when assessing the overall incidence of COVID-19 in the cohort of patients 
with CTD compared with the general population. 
 These preliminary data seem to suggest that our approach of encour-
aging patients with CTD to maintain ongoing rheumatological therapy and 
to adhere strictly to the norms to avoid infection has prevented rheumatic 
disease relapse without increasing the risk of COVID-19. While waiting for 
our results to be confirmed on larger samples, this information can certainly 
be useful to all rheumatologists worldwide facing the pandemic.
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